Conjugated Estrogens Topical Dosage
Medically reviewed on September 6, 2018.
Applies to the following strengths: 0.625 mg/g
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Atrophic Vaginitis
Initial dose: 0.5 grams intravaginally in a cyclic regimen: daily for 21 days, then off for 7 days
Maintenance dose: 0.5 to 2 grams intravaginally in a cyclic regimen: daily for 21 days, then off for 7 days
-Adjust dose based on individual response
Uses: Treatment of atrophic vaginitis and kraurosis vulvae
Usual Adult Dose for Postmenopausal Symptoms
0.5 grams intravaginally twice weekly (e.g. Monday and Thursday)
0.5 grams intravaginally in a cyclic regimen: daily for 21 days, then off for 7 days
Uses: Treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Endometrial cancer, cardiovascular disorders, breast cancer and probable dementia:
Estrogen Only Therapy:
-There is an increased risk of endometrial cancer in women with uteruses using unopposed estrogens.
-The Women's Health Initiative (WHI) estrogen along substudy reported increased risk of stroke and deep vein thrombosis (DVT).
-The WHI Memory Study (WHIMS) reported an increased risk of probable dementia in postmenopausal women 65 years and older on estrogen-alone therapy.
-Estrogen alone therapy should not be used for prevention of cardiovascular disease or dementia.
Estrogen Plus Progestin Therapy:
-Estrogen plus progestin increased risks of stroke, DVT, pulmonary embolism (PE), and myocardial infarction (MI) in the WHI substudy.
-Estrogen plus progestin increased the risk of invasive breast cancer in the WHI substudy.
-Estrogen plus progestin therapy increased the risk of probable dementia in postmenopausal women 65 years and older in the WHIMS study.
-Estrogen plus progestin should not be used for prevention of cardiovascular disease or dementia.
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Data not available
-Generally, a postmenopausal woman with a uterus should have a progestin added to reduce the risk of endometrial cancer.
-Women without a uterus do not need progestin, except some patients with a history of endometriosis may need a progestin.
-Use at the lowest effective dose for the shortest duration consistent with treatment goals.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about conjugated estrogens topical
- Conjugated estrogens topical Side Effects
- During Pregnancy
- Drug Interactions
- 5 Reviews
- Drug class: estrogens
- Conjugated estrogens vaginal
- Estrogens (Conjugated/Equine, Topical)
- Conjugated estrogens Vaginal (Advanced Reading)